Yubo International Biotech Ltd (YBGJ) Form 10-Q — May 15, 2026
Yubo International Biotech Ltd reported zero revenue and a net loss of $295,026 for the quarter ended March 31, 2026, highlighting its inability to generate commercial sales despite offering health management services and stem cell products. The company disclosed a going-concern risk, citing only $10,382 in cash and negative working capital of $2.4 million. It relies on a financial support letter from President Jun Wang and existing shareholder loans to meet liabilities for the next 12 months. Operating expenses decreased 38% year-over-year to $289,274, driven by lower occupancy costs and reduced employee compensation.
Key figures
- Revenue
- 0
- Cash Position
- 10382
- Operating Expenses
- 289274
- Shares Outstanding
- 170420790
Price after filing
Close on the filing date to close N calendar days later (from $0.01). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.